Bio-Techne Corp Financials
This page shows Bio-Techne Corp (TECH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Gross-profit-rich sales are being increasingly absorbed by operating overhead, while low reinvestment needs keep cash sturdier than earnings.
From FY2024 to FY2025, gross profit increased only$21M while SG&A increased$122M , so the earnings drop reflects overhead expansion overwhelming modest growth. Even with that squeeze, free cash flow held at$257M because capex was just$31M , meaning reported profit weakened far faster than cash generation.
Across FY2022-FY2025, gross margin stayed near the mid-60s, but operating margin fell from
Liquidity still looks comfortable, with a current ratio of 3.5x and debt-to-equity of 0.2x in FY2025, so the company is not relying on a stretched balance sheet to fund the squeeze. But goodwill at
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bio-Techne Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bio-Techne Corp has an operating margin of 8.4%, meaning the company retains $8 of operating profit per $100 of revenue. This strong profitability earns a score of 74/100, reflecting efficient cost management and pricing power. This is down from 17.8% the prior year.
Bio-Techne Corp's revenue grew 5.2% year-over-year to $1.2B, a solid pace of expansion. This earns a growth score of 45/100.
Bio-Techne Corp has a moderate D/E ratio of 0.18. This balance of debt and equity financing earns a leverage score of 50/100.
With a current ratio of 3.46, Bio-Techne Corp holds $3.46 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 82/100.
Bio-Techne Corp converts 21.0% of revenue into free cash flow ($256.6M). This strong cash generation earns a score of 87/100.
Bio-Techne Corp's ROE of 3.8% shows moderate profitability relative to equity, earning a score of 58/100. This is down from 8.1% the prior year.
Bio-Techne Corp scores 11.80, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($11.1B) relative to total liabilities ($639.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bio-Techne Corp passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Bio-Techne Corp generates $3.92 in operating cash flow ($287.6M OCF vs $73.4M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Bio-Techne Corp earns $12.0 in operating income for every $1 of interest expense ($102.3M vs $8.5M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Bio-Techne Corp generated $1.2B in revenue in fiscal year 2025. This represents an increase of 5.2% from the prior year.
Bio-Techne Corp's EBITDA was $212.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 33.4% from the prior year.
Bio-Techne Corp reported $73.4M in net income in fiscal year 2025. This represents a decrease of 56.3% from the prior year.
Bio-Techne Corp earned $0.46 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 56.2% from the prior year.
Cash & Balance Sheet
Bio-Techne Corp generated $256.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 8.7% from the prior year.
Bio-Techne Corp held $162.2M in cash against $346.0M in long-term debt as of fiscal year 2025.
Bio-Techne Corp paid $0.32 per share in dividends in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Bio-Techne Corp had 155M shares outstanding in fiscal year 2025. This represents a decrease of 2.1% from the prior year.
Margins & Returns
Bio-Techne Corp's gross margin was 64.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.6 percentage points from the prior year.
Bio-Techne Corp's operating margin was 8.4% in fiscal year 2025, reflecting core business profitability. This is down 9.4 percentage points from the prior year.
Bio-Techne Corp's net profit margin was 6.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 8.5 percentage points from the prior year.
Bio-Techne Corp's ROE was 3.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 4.3 percentage points from the prior year.
Capital Allocation
Bio-Techne Corp invested $99.5M in research and development in fiscal year 2025. This represents an increase of 2.9% from the prior year.
Bio-Techne Corp spent $275.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 244.5% from the prior year.
Bio-Techne Corp invested $31.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 50.7% from the prior year.
TECH Income Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $311.4M+5.3% | $295.9M+3.3% | $286.6M-9.6% | $317.0M+0.2% | $316.2M+6.4% | $297.0M+2.6% | $289.5M-5.4% | $306.1M |
| Cost of Revenue | $103.1M-1.4% | $104.6M+6.3% | $98.4M-16.7% | $118.2M+16.3% | $101.6M-1.5% | $103.1M-3.1% | $106.4M+3.6% | $102.8M |
| Gross Profit | $208.3M+8.9% | $191.3M+1.7% | $188.1M-5.4% | $198.8M-7.3% | $214.6M+10.7% | $193.9M+5.9% | $183.0M-10.0% | $203.3M |
| R&D Expenses | $23.5M+1.4% | $23.1M-4.6% | $24.2M-6.9% | $26.0M+5.9% | $24.6M-1.7% | $25.0M+4.8% | $23.9M-0.5% | $24.0M |
| SG&A Expenses | $109.3M-3.8% | $113.7M-2.2% | $116.2M-40.9% | $196.6M+30.0% | $151.3M+24.6% | $121.5M+1.9% | $119.2M-10.8% | $133.5M |
| Operating Income | $75.5M+38.6% | $54.5M+14.3% | $47.7M+299.7% | -$23.9M-161.6% | $38.7M-18.4% | $47.4M+18.6% | $40.0M-12.7% | $45.8M |
| Interest Expense | $2.4M+10.6% | $2.2M-26.0% | $2.9M+34.7% | $2.2M+8.5% | $2.0M-6.6% | $2.1M-1.3% | $2.2M-13.3% | $2.5M |
| Income Tax | $20.2M+57.9% | $12.8M+30.3% | $9.8M+289.3% | -$5.2M-133.0% | $15.7M+96.4% | $8.0M+21.5% | $6.6M+513.0% | $1.1M |
| Net Income | $51.0M+34.3% | $38.0M-0.5% | $38.2M+316.0% | -$17.7M-178.3% | $22.6M-35.3% | $34.9M+3.8% | $33.6M-17.2% | $40.6M |
| EPS (Diluted) | $0.32+33.3% | $0.240.0% | $0.24 | N/A | $0.14-36.4% | $0.22+4.8% | $0.21 | N/A |
TECH Balance Sheet
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.6B+1.1% | $2.5B-0.1% | $2.5B-1.2% | $2.6B-3.3% | $2.6B-1.0% | $2.7B-2.4% | $2.7B+1.2% | $2.7B |
| Current Assets | $688.0M+7.9% | $637.4M+4.6% | $609.5M+0.2% | $608.3M-3.0% | $627.2M-1.2% | $634.6M-2.1% | $648.6M+5.0% | $617.4M |
| Cash & Equivalents | $209.8M+21.4% | $172.9M+19.3% | $145.0M-10.6% | $162.2M+15.3% | $140.7M-20.8% | $177.5M-5.3% | $187.5M+23.6% | $151.8M |
| Inventory | $201.2M-2.1% | $205.4M+1.1% | $203.2M+7.3% | $189.4M-0.9% | $191.1M+1.4% | $188.4M+1.8% | $185.0M+3.0% | $179.7M |
| Accounts Receivable | $214.6M+16.2% | $184.6M+0.4% | $183.9M-11.1% | $206.9M-12.8% | $237.1M+8.8% | $217.9M-2.6% | $223.7M-7.3% | $241.4M |
| Goodwill | $977.8M-0.3% | $980.6M+0.2% | $978.9M-0.2% | $980.9M+1.3% | $968.6M+0.4% | $964.6M-1.8% | $982.6M+1.0% | $972.7M |
| Total Liabilities | $465.3M-9.1% | $511.7M-8.7% | $560.3M-12.3% | $639.1M+2.0% | $626.2M+5.8% | $591.9M-0.9% | $597.4M-5.9% | $635.0M |
| Current Liabilities | $153.3M+9.2% | $140.4M-2.8% | $144.5M-17.8% | $175.8M+3.9% | $169.2M+4.9% | $161.3M+13.5% | $142.1M-10.8% | $159.4M |
| Long-Term Debt | $200.0M-23.1% | $260.0M-13.3% | $300.0M-13.3% | $346.0M+4.8% | $330.0M+10.0% | $300.0M0.0% | $300.0M-6.0% | $319.0M |
| Total Equity | $2.1B+3.7% | $2.0B+2.3% | $2.0B+2.4% | $1.9B-4.9% | $2.0B-2.9% | $2.1B-2.8% | $2.1B+3.4% | $2.1B |
| Retained Earnings | $1.1B+3.5% | $1.1B+2.2% | $1.1B+1.5% | $1.1B-10.9% | $1.2B-7.0% | $1.3B-4.1% | $1.3B+1.2% | $1.3B |
TECH Cash Flow Statement
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $86.7M+5.2% | $82.4M+198.8% | $27.6M-71.9% | $98.2M+138.8% | $41.1M-51.2% | $84.3M+32.0% | $63.9M-15.4% | $75.5M |
| Capital Expenditures | $9.1M+53.5% | $5.9M+10.4% | $5.4M+9.7% | $4.9M-51.7% | $10.1M+48.4% | $6.8M-25.6% | $9.2M-49.0% | $18.0M |
| Free Cash Flow | $77.6M+1.4% | $76.5M+244.2% | $22.2M-76.2% | $93.3M+201.0% | $31.0M-60.0% | $77.5M+41.7% | $54.7M-4.9% | $57.5M |
| Investing Cash Flow | -$5.8M+1.8% | -$5.9M-1078.7% | $605K+49.0% | $406K+104.6% | -$8.9M-76.3% | -$5.0M+76.8% | -$21.7M-146.2% | -$8.8M |
| Financing Cash Flow | -$42.7M+12.8% | -$49.0M-10.8% | -$44.2M+51.1% | -$90.5M-32.9% | -$68.0M+18.8% | -$83.8M-624.5% | -$11.6M+80.7% | -$60.1M |
| Dividends Paid | $12.5M+0.4% | $12.5M+0.2% | $12.4M+0.5% | $12.4M-1.5% | $12.6M-1.2% | $12.7M+0.4% | $12.7M+0.5% | $12.6M |
| Share Buybacks | $0 | $0-100.0% | $24K-100.0% | $100.1M0.0% | $100.0M | N/A | N/A | $0 |
TECH Financial Ratios
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.9%+2.2pp | 64.6%-1.0pp | 65.6%+2.9pp | 62.7%-5.1pp | 67.9%+2.6pp | 65.3%+2.0pp | 63.2%-3.2pp | 66.4% |
| Operating Margin | 24.2%+5.8pp | 18.4%+1.8pp | 16.6%+24.2pp | -7.5%-19.8pp | 12.2%-3.7pp | 16.0%+2.1pp | 13.8%-1.2pp | 15.0% |
| Net Margin | 16.4%+3.5pp | 12.8%-0.5pp | 13.3%+18.9pp | -5.6%-12.7pp | 7.1%-4.6pp | 11.8%+0.1pp | 11.6%-1.7pp | 13.3% |
| Return on Equity | 2.5%+0.6pp | 1.9%-0.1pp | 1.9%+2.9pp | -0.9%-2.0pp | 1.1%-0.6pp | 1.7%+0.1pp | 1.6%-0.4pp | 2.0% |
| Return on Assets | 2.0%+0.5pp | 1.5%0.0pp | 1.5%+2.2pp | -0.7%-1.5pp | 0.9%-0.5pp | 1.3%+0.1pp | 1.2%-0.3pp | 1.5% |
| Current Ratio | 4.49-0.1 | 4.54+0.3 | 4.22+0.8 | 3.46-0.2 | 3.71-0.2 | 3.94-0.6 | 4.56+0.7 | 3.87 |
| Debt-to-Equity | 0.10-0.0 | 0.13-0.0 | 0.15-0.0 | 0.18+0.0 | 0.16+0.0 | 0.140.0 | 0.14-0.0 | 0.15 |
| FCF Margin | 24.9%-0.9pp | 25.9%+18.1pp | 7.8%-21.7pp | 29.4%+19.6pp | 9.8%-16.3pp | 26.1%+7.2pp | 18.9%+0.1pp | 18.8% |
Similar Companies
Frequently Asked Questions
What is Bio-Techne Corp's annual revenue?
Bio-Techne Corp (TECH) reported $1.2B in total revenue for fiscal year 2025. This represents a 5.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bio-Techne Corp's revenue growing?
Bio-Techne Corp (TECH) revenue grew by 5.2% year-over-year, from $1.2B to $1.2B in fiscal year 2025.
Is Bio-Techne Corp profitable?
Yes, Bio-Techne Corp (TECH) reported a net income of $73.4M in fiscal year 2025, with a net profit margin of 6.0%.
What is Bio-Techne Corp's EBITDA?
Bio-Techne Corp (TECH) had EBITDA of $212.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Bio-Techne Corp have?
As of fiscal year 2025, Bio-Techne Corp (TECH) had $162.2M in cash and equivalents against $346.0M in long-term debt.
What is Bio-Techne Corp's gross margin?
Bio-Techne Corp (TECH) had a gross margin of 64.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bio-Techne Corp's operating margin?
Bio-Techne Corp (TECH) had an operating margin of 8.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Bio-Techne Corp's net profit margin?
Bio-Techne Corp (TECH) had a net profit margin of 6.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Bio-Techne Corp pay dividends?
Yes, Bio-Techne Corp (TECH) paid $0.32 per share in dividends during fiscal year 2025.
What is Bio-Techne Corp's return on equity (ROE)?
Bio-Techne Corp (TECH) has a return on equity of 3.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bio-Techne Corp's free cash flow?
Bio-Techne Corp (TECH) generated $256.6M in free cash flow during fiscal year 2025. This represents a 8.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bio-Techne Corp's operating cash flow?
Bio-Techne Corp (TECH) generated $287.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bio-Techne Corp's total assets?
Bio-Techne Corp (TECH) had $2.6B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bio-Techne Corp's capital expenditures?
Bio-Techne Corp (TECH) invested $31.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bio-Techne Corp spend on research and development?
Bio-Techne Corp (TECH) invested $99.5M in research and development during fiscal year 2025.
What is Bio-Techne Corp's current ratio?
Bio-Techne Corp (TECH) had a current ratio of 3.46 as of fiscal year 2025, which is generally considered healthy.
What is Bio-Techne Corp's debt-to-equity ratio?
Bio-Techne Corp (TECH) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bio-Techne Corp's return on assets (ROA)?
Bio-Techne Corp (TECH) had a return on assets of 2.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bio-Techne Corp's Altman Z-Score?
Bio-Techne Corp (TECH) has an Altman Z-Score of 11.80, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bio-Techne Corp's Piotroski F-Score?
Bio-Techne Corp (TECH) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bio-Techne Corp's earnings high quality?
Bio-Techne Corp (TECH) has an earnings quality ratio of 3.92x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bio-Techne Corp cover its interest payments?
Bio-Techne Corp (TECH) has an interest coverage ratio of 12.0x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Bio-Techne Corp?
Bio-Techne Corp (TECH) scores 66 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.